RANELL EARL: Open Payments
NPI 1407683113 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$71 in 4 payments from 4 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $71
Food & beverage: $71
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: AIRSUPRA, XIFAXAN, REXULTI, CAPLYTA.
Industry payments across TX — which companies pay providers there.
